Abstract

Fas ligand expression by cells of the vessel wall has been proposed to play a role in normal and pathologic conditions. Genetic engineering of vascularized organs for endothelial cell (EC) expression of FasL could protect the endothelium and underlying tissues from infiltrating Fas+ leukocytes. Nevertheless, the endogenous expression of FasL by ECs of different species and the potential deleterious effects of enforced FasL expression by ECs are largely unknown. In human ECs, levels of FLICE/caspase 8-inhibitory protein (FLIP) have been shown to control apoptosis mediated by Fas. Cell surface expression of FasL in rat, mouse, human, and pig ECs was obtained using recombinant adenoviruses or transient plasmid transfection assays. FasL expression was evaluated by FACS analysis and cytotoxicity assays. Apoptosis was evaluated using annexin V, TUNEL, and cytotoxicity assays. FLIP levels were evaluated by Western blot analysis and overexpression was obtained by transient transfection. Analysis of ECs from different species showed that FasL was predominantly present in the cytoplasm, and depending on the species, little or no cell surface expression was detected. Enforced cell surface expression of FasL on rat or mouse ECs, either in culture or within the vessel wall resulted in massive apoptosis. In contrast, porcine or human ECs were completely resistant to apoptosis mediated by Fas-FasL interaction. Markedly reduced FLIP levels were observed in rat and mouse ECs compared to human and porcine ECs. Overexpression of FLIP in rat ECs conferred protection against cell surface expression of FasL. The consequences of FasL overexpression depend on the subcellular compartment and species in which FasL enforced expression is targeted and this is at least partially related to FLIP levels.

Highlights

  • Fas ligand (FasL, APO-1L, or CD95L) is a type II transmembrane protein of 37–40 kDa that belongs to the tumor necrosis factor (TNF) family [1]

  • Despite human endothelial cell (EC) having been described as being resistant to Fas-mediated apoptosis and expression of cell-surface FasL [20], we hypothesized that failure to obtain transgenic rats expressing significant levels of cell membrane FasL could be due to uterine loss of animals expressing FasL due to leaky expression of the tetracycline-inducible system and sensitivity of rat ECs to FasL-mediated apoptosis

  • Transduction of aortas with AdFasL resulted in massive apoptosis of ECs (Fig. 5D). These results indicate that FasL expression in rat ECs within normal quiescent endothelium results in apoptosis

Read more

Summary

Introduction

Fas ligand (FasL, APO-1L, or CD95L) is a type II transmembrane protein of 37–40 kDa that belongs to the tumor necrosis factor (TNF) family [1]. FasL interacts with its receptor Fas (APO-1, CD95), a member of the TNF receptor family expressed in many different cell types. In human ECs, levels of FLICE/caspase 8-inhibitory protein (FLIP) have been shown to control apoptosis mediated by Fas. Materials and Methods: Cell surface expression of FasL in rat, mouse, human, and pig ECs was obtained using recombinant adenoviruses or transient plasmid transfection assays. Results: Analysis of ECs from different species showed that FasL was predominantly present in the cytoplasm, and depending on the species, little or no cell surface expression was detected. Enforced cell surface expression of FasL on rat or mouse ECs, either in culture or within the vessel wall resulted in massive apoptosis. Reduced FLIP levels were observed in rat and mouse ECs compared to human and porcine ECs. Overexpression of FLIP in rat ECs conferred protection against cell surface expression of FasL. Conclusions: The consequences of FasL overexpression depend on the subcellular compartment and species in which FasL enforced expression is targeted and this is at least partially related to FLIP levels

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call